Scandium-47 [T-1/2 = 3.35 d, E-(max.) = 600 keV, E = 159 keV] is a relatively new radioisotope that holds tremendous potential for use in cancer theranostics. The radioisotope was produced by thermal neutron irradiation of enriched Ca-46 producing Ca-47, which decays by (-) emission to Sc-47. A viable method based on the selective electroamalgamation of Ca2+ ions has been developed for the clinical-scale separation of Sc-47 from Ca-47. The overall yield of Sc-47 after the separation process was >80% and it was obtained with >99.9% radionuclidic purity in a form suitable for radiopharmaceutical preparation. This strategy holds promise for future clinical translation of this radioisotope.